Miami-based TissueTech recently announced the completion of a $10 million round of growth equity financing from Ballast Point Ventures and River Cities Capital Funds.
TissueTech is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. The funding will be largely used to accelerate commercial efforts and further research and development, the company said. “We are excited to welcome the expertise of two outstanding investment partners. Their wealth of experience in guiding the development and evolution of other successful growth-stage companies will serve as a tremendous resource for the future of TissueTech,” said Dr. Scheffer Tseng, TissueTech’s chairman and chief scientific officer.
Edwards Wildman represented the venture capital firms in the deal. The deal team was led by Edwards Wildman’s John Igoe and Tamer Tullgren.
Ballast Point Ventures, a later stage venture capital fund, is based in St. Petersburg, Fla. River Cities Capital Funds is headquartered in Cincinnati, Ohio.